August 03, 2025 a 11:43 am
ABT: Fundamental Ratio Analysis - Abbott Laboratories
Abbott Laboratories has a diversified product portfolio within the healthcare sector, operating across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Despite a diverse and robust product line, current fundamental ratings suggest room for improvement. The stock remains a viable contender in the healthcare industry due to its broad product reach and longstanding market presence.
Fundamental Rating
Current fundamental analysis shows a moderate performance with specific areas requiring attention, such as return on equity and assets.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 1 | |
| Return on Assets | 1 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
Historical data suggests consistency in fundamental scores, reflecting a stable, though not exceptional, performance over recent periods.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-08-01 | 1 | 4 | 1 | 1 | 1 | 1 | 1 |
| Previous | 0 | 4 | 1 | 1 | 1 | 1 | 1 |
Analyst Price Targets
Analysts have set a consistent price target, suggesting an optimistic but cautious outlook for Abbott Laboratories.
| High | Low | Median | Consensus |
|---|---|---|---|
| 147 | 147 | 147 | 147 |
Analyst Sentiment
Analyst sentiment is generally positive, with no negative recommendations recorded; this reflects a favorable outlook among professional analysts.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 29 | |
| Hold | 9 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Abbott Laboratories remains a stalwart in the healthcare segment, with diverse operations that provide resilience in its stock offerings. While fundamental scores suggest some weaknesses, the consistent price targets and positive analyst sentiment lend confidence to its potential growth. The current landscape offers opportunities for risk-tolerant investors while underlining the need for continued scrutiny on fundamental performance. Overall, Abbott Laboratories is positioned to capitalize on its broad reach and established market presence.